Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Leukemia, Myeloid, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Peripheral Blood Stem Cell Transplantation 7Busulfan 5ruxolitinib 4Methotrexate 4Cyclosporine 4fludarabine phosphate 3Whole-Body Irradiation 2Mycophenolic Acid 2Flow Cytometry 2Cytogenetic Analysis 2Cytarabine 2Cyclophosphamide 2Antilymphocyte Serum 2venetoclax 1sonidegib 1pomalidomide 1pevonedistat 1pelcitoclax 1lestaurtinib 1givinostat hydrochloride 1givinostat 1ethanolamine oleate 1aldesleukin 1Vitamin E 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Topotecan 1Tacrolimus 1Sulfamethoxazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Polycythemia Vera × lestaurtinib × Clear all
NCT00668421 2014-11-26

CEP-701 (Lestaurtinib) in Myelofibrosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Unknown
60 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡